How CDMOs Turn “Undruggable” Into “Developable”
AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine how precision medicine, AI, and advanced discovery tools are expanding what is possible in drug development while creating new formulation and manufacturing challenges. As researchers pursue more targeted molecules, many candidates come with difficult chemistry, including poor solubility, low permeability, stability concerns, and scale-up risk. The…
Read MoreBeyond Solvents: The Future of Sustainable Amorphous Dispersion Development
AustinPx CEO Elizabeth Hickman examines why greener amorphous solid dispersion (ASD) development requires more than simply reducing solvent use. As sustainability expectations grow, she explains how cost, risk, timelines, and long-term asset value are all shaped by the complexity of the manufacturing process itself. The article explores how traditional solvent-based ASD approaches can introduce added…
Read More